Who
Jill O'Donnell-Tormey
Director
Company insider
Files Form 4 as: Director, Coherus Oncology.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 18 May 2022
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,250 at $0.00 | filing |
| 18 May 2022filed 20 May 2022 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.